Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancer
Tumor antigens (TAs) can initiate host immune responses and produce TA-associated autoantibody (TAAbs), potential cancer biomarkers. Sputum is directly generated from the upper and lower airways, and thus can be used as a surrogate sample for the diagnosis of lung cancer based on molecular analysis....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-02-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320304836 |
| _version_ | 1818430414154366976 |
|---|---|
| author | Ning Li Van K. Holden Janaki Deepak Nevins W. Todd Feng Jiang |
| author_facet | Ning Li Van K. Holden Janaki Deepak Nevins W. Todd Feng Jiang |
| author_sort | Ning Li |
| collection | DOAJ |
| description | Tumor antigens (TAs) can initiate host immune responses and produce TA-associated autoantibody (TAAbs), potential cancer biomarkers. Sputum is directly generated from the upper and lower airways, and thus can be used as a surrogate sample for the diagnosis of lung cancer based on molecular analysis. To develop sputum TAAb biomarkers for the early detection of lung cancer, the leading cause of cancer death, we probed a protein microarray containing more than 9,000 antigens with sputum supernatants of a discovery set of 30 lung cancer patients and 30 cancer-free smokers. Twenty-eight TAs with higher reactivity in sputum of lung cancer cases vs. controls were identified. The diagnostic significance of TAAbs against the TAs was determined by enzyme-linked immunosorbent assays (ELISAs) in sputum of the discovery set and additional 166 lung cancer patients and 213 cancer-free smokers (validation set). Three sputum TAAbs against DDX6, ENO1, and 14–3-3ζ were developed as a biomarker panel with 81% sensitivity and 83% specificity for diagnosis of lung cancer, regardless of stages, locations, and histological types of lung tumors. This study provides the first evidence that sputum TAAbs could be used as biomarkers for the early detection of lung cancer. |
| first_indexed | 2024-12-14T15:33:02Z |
| format | Article |
| id | doaj.art-f91a7f65fa6d4ee2b58d49fc0b16069b |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-14T15:33:02Z |
| publishDate | 2021-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-f91a7f65fa6d4ee2b58d49fc0b16069b2022-12-21T22:55:49ZengElsevierTranslational Oncology1936-52332021-02-01142100991Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancerNing Li0Van K. Holden1Janaki Deepak2Nevins W. Todd3Feng Jiang4Departments of Medicine, University of Maryland School of Medicine, Baltimore, MD, USADepartments of Medicine, University of Maryland School of Medicine, Baltimore, MD, USADepartments of Medicine, University of Maryland School of Medicine, Baltimore, MD, USADepartments of Medicine, University of Maryland School of Medicine, Baltimore, MD, USACorresponding author.; Departments of Medicine, University of Maryland School of Medicine, Baltimore, MD, USATumor antigens (TAs) can initiate host immune responses and produce TA-associated autoantibody (TAAbs), potential cancer biomarkers. Sputum is directly generated from the upper and lower airways, and thus can be used as a surrogate sample for the diagnosis of lung cancer based on molecular analysis. To develop sputum TAAb biomarkers for the early detection of lung cancer, the leading cause of cancer death, we probed a protein microarray containing more than 9,000 antigens with sputum supernatants of a discovery set of 30 lung cancer patients and 30 cancer-free smokers. Twenty-eight TAs with higher reactivity in sputum of lung cancer cases vs. controls were identified. The diagnostic significance of TAAbs against the TAs was determined by enzyme-linked immunosorbent assays (ELISAs) in sputum of the discovery set and additional 166 lung cancer patients and 213 cancer-free smokers (validation set). Three sputum TAAbs against DDX6, ENO1, and 14–3-3ζ were developed as a biomarker panel with 81% sensitivity and 83% specificity for diagnosis of lung cancer, regardless of stages, locations, and histological types of lung tumors. This study provides the first evidence that sputum TAAbs could be used as biomarkers for the early detection of lung cancer.http://www.sciencedirect.com/science/article/pii/S1936523320304836Lung cancerSputumAutoantibodiesBiomarkersDiagnosis |
| spellingShingle | Ning Li Van K. Holden Janaki Deepak Nevins W. Todd Feng Jiang Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancer Translational Oncology Lung cancer Sputum Autoantibodies Biomarkers Diagnosis |
| title | Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancer |
| title_full | Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancer |
| title_fullStr | Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancer |
| title_full_unstemmed | Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancer |
| title_short | Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancer |
| title_sort | autoantibodies against tumor associated antigens in sputum as biomarkers for lung cancer |
| topic | Lung cancer Sputum Autoantibodies Biomarkers Diagnosis |
| url | http://www.sciencedirect.com/science/article/pii/S1936523320304836 |
| work_keys_str_mv | AT ningli autoantibodiesagainsttumorassociatedantigensinsputumasbiomarkersforlungcancer AT vankholden autoantibodiesagainsttumorassociatedantigensinsputumasbiomarkersforlungcancer AT janakideepak autoantibodiesagainsttumorassociatedantigensinsputumasbiomarkersforlungcancer AT nevinswtodd autoantibodiesagainsttumorassociatedantigensinsputumasbiomarkersforlungcancer AT fengjiang autoantibodiesagainsttumorassociatedantigensinsputumasbiomarkersforlungcancer |